METHODS: Premenopausal women (18-50 years) with cyclic excessive uterine bleeding,
and≥ 1 discrete UF were randomized to once daily UPA 10 mg, UPA 5 mg, or placebo for …

Background To evaluate the psychometric and measurement properties of two patient-
reported outcome instruments, the menstrual pictogram superabsorbent polymer-containing …

ABSTRACT Introduction: Uterine fibroids (UFs) are the most prevalent benign neoplastic
threat originating from myometria of reproductive age women, with a profound financial load …

Background: Women with uterine fibroids (UFs) experience many clinical manifestations that
affect their quality of life (QOL). The Uterine Fibroid Symptom and Health-related Quality of …

Objective To compare long-term health-related quality of life (HRQOL) 1 year after
hysterectomy or myomectomy for treatment of uterine fibroids (UFs) and to determine …

Background The oral gonadotropin-releasing hormone antagonist relugolix, which
temporarily stops menstruation, is used to treat heavy menstrual bleeding, pelvic pressure …

METHODS: Female participants (≥ 18 years) were recruited via email from GfK
KnowledgePanel®, a nationally representative panel of US households, supplemented with …

Background: Uterine fibroids (UF) are associated with significant health-related quality of life
(HRQL) impact. This study examined the impact of UF symptoms on HRQL. Methods: An …

Objective To evaluate symptomatic uterine fibroid outcomes following at least one course of
ulipristal acetate (UPA) 5 mg/day therapy in the hospital setting, during the year 2017. Study …

Background: Quality of life (QOL) and psychological health has been reported to be
decreased among women with gynecological conditions such as uterine fibroids (UFs) …